Literature DB >> 26923591

DNMT3b Modulates Melanoma Growth by Controlling Levels of mTORC2 Component RICTOR.

Goran Micevic1, Viswanathan Muthusamy2, William Damsky3, Nicholas Theodosakis1, Xiaoni Liu4, Katrina Meeth4, Emily Wingrove4, Manjula Santhanakrishnan5, Marcus Bosenberg6.   

Abstract

DNA methyltransferase DNMT3B is frequently overexpressed in tumor cells and plays important roles during the formation and progression of several cancer types. However, the specific signaling pathways controlled by DNMT3B in cancers, including melanoma, are poorly understood. Here, we report that DNMT3B plays a pro-tumorigenic role in human melanoma and that DNMT3B loss dramatically suppresses melanoma formation in the Braf/Pten mouse melanoma model. Loss of DNMT3B results in hypomethylation of the miR-196b promoter and increased miR-196b expression, which directly targets the mTORC2 component Rictor. Loss of RICTOR in turn prevents mTORC2 activation, which is critical for melanoma formation and growth. These findings establish Dnmt3b as a regulator of melanoma formation through its effect on mTORC2 signaling. Based on these results, DNMT3B is a potential therapeutic target in melanoma.
Copyright © 2016 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26923591      PMCID: PMC4785087          DOI: 10.1016/j.celrep.2016.02.010

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  59 in total

1.  Expression of mRNA for DNA methyltransferases and methyl-CpG-binding proteins and DNA methylation status on CpG islands and pericentromeric satellite regions during human hepatocarcinogenesis.

Authors:  Y Saito; Y Kanai; M Sakamoto; H Saito; H Ishii; S Hirohashi
Journal:  Hepatology       Date:  2001-03       Impact factor: 17.425

2.  Epigenetic PTEN silencing in malignant melanomas without PTEN mutation.

Authors:  X P Zhou; O Gimm; H Hampel; T Niemann; M J Walker; C Eng
Journal:  Am J Pathol       Date:  2000-10       Impact factor: 4.307

3.  Mutation and allelic loss of the PTEN/MMAC1 gene in primary and metastatic melanoma biopsies.

Authors:  A Birck; V Ahrenkiel; J Zeuthen; K Hou-Jensen; P Guldberg
Journal:  J Invest Dermatol       Date:  2000-02       Impact factor: 8.551

Review 4.  DNA methylation and gene silencing in cancer.

Authors:  Stephen B Baylin
Journal:  Nat Clin Pract Oncol       Date:  2005-12

5.  mTORC1 activation blocks BrafV600E-induced growth arrest but is insufficient for melanoma formation.

Authors:  William Damsky; Goran Micevic; Katrina Meeth; Viswanathan Muthusamy; David P Curley; Manjula Santhanakrishnan; Ildiko Erdelyi; James T Platt; Laura Huang; Nicholas Theodosakis; M Raza Zaidi; Scott Tighe; Michael A Davies; David Dankort; Martin McMahon; Glenn Merlino; Nabeel Bardeesy; Marcus Bosenberg
Journal:  Cancer Cell       Date:  2015-01-12       Impact factor: 31.743

Review 6.  The epigenomics of cancer.

Authors:  Peter A Jones; Stephen B Baylin
Journal:  Cell       Date:  2007-02-23       Impact factor: 41.582

7.  Characterization of melanocyte-specific inducible Cre recombinase transgenic mice.

Authors:  Marcus Bosenberg; Viswanathan Muthusamy; David P Curley; Zhenxiong Wang; Cara Hobbs; Betsy Nelson; Cristina Nogueira; James W Horner; Ronald Depinho; Lynda Chin
Journal:  Genesis       Date:  2006-05       Impact factor: 2.487

8.  Nivolumab plus ipilimumab in advanced melanoma.

Authors:  Jedd D Wolchok; Harriet Kluger; Margaret K Callahan; Michael A Postow; Naiyer A Rizvi; Alexander M Lesokhin; Neil H Segal; Charlotte E Ariyan; Ruth-Ann Gordon; Kathleen Reed; Matthew M Burke; Anne Caldwell; Stephanie A Kronenberg; Blessing U Agunwamba; Xiaoling Zhang; Israel Lowy; Hector David Inzunza; William Feely; Christine E Horak; Quan Hong; Alan J Korman; Jon M Wigginton; Ashok Gupta; Mario Sznol
Journal:  N Engl J Med       Date:  2013-06-02       Impact factor: 91.245

9.  Mahanine restores RASSF1A expression by down-regulating DNMT1 and DNMT3B in prostate cancer cells.

Authors:  Soumik Agarwal; Karishma S Amin; Shankar Jagadeesh; Gokul Baishay; Paruchuri G Rao; Nabin C Barua; Samir Bhattacharya; Partha P Banerjee
Journal:  Mol Cancer       Date:  2013-08-30       Impact factor: 27.401

10.  Significance of DNMT3b in oral cancer.

Authors:  Wen-Cheng Chen; Miao-Fen Chen; Paul-Yang Lin
Journal:  PLoS One       Date:  2014-03-13       Impact factor: 3.240

View more
  31 in total

Review 1.  The emerging role of PI3K/AKT-mediated epigenetic regulation in cancer.

Authors:  Jennifer M Spangle; Thomas M Roberts; Jean J Zhao
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2017-03-14       Impact factor: 10.680

2.  Structure-Guided Identification of DNMT3B Inhibitors.

Authors:  Ana S Newton; John C Faver; Goran Micevic; Viswanathan Muthusamy; Shalley N Kudalkar; Nicole Bertoletti; Karen S Anderson; Marcus W Bosenberg; William L Jorgensen
Journal:  ACS Med Chem Lett       Date:  2020-02-07       Impact factor: 4.345

Review 3.  Melanocytic nevi and melanoma: unraveling a complex relationship.

Authors:  W E Damsky; M Bosenberg
Journal:  Oncogene       Date:  2017-06-12       Impact factor: 9.867

4.  The role of SHMT2 in modulating lipid metabolism in hepatocytes via glycine-mediated mTOR activation.

Authors:  You-Jin Choi; Geunhye Lee; Sung Ho Yun; Wonseok Lee; Jieun Yu; Sang Kyum Kim; Byung-Hoon Lee
Journal:  Amino Acids       Date:  2022-02-25       Impact factor: 3.520

5.  DRONE: Direct Tracking of DNA Cytidine Deamination and Other DNA Modifying Activities.

Authors:  Tomoaki Sasaki; Shalley N Kudalkar; Nicole Bertoletti; Karen S Anderson
Journal:  Anal Chem       Date:  2018-09-28       Impact factor: 6.986

6.  Targeting mTORC2 component rictor inhibits cell proliferation and promotes apoptosis in gastric cancer.

Authors:  Yu-Hai Bian; Jia Xu; Wen-Yi Zhao; Zi-Zhen Zhang; Lin Tu; Hui Cao; Zhi-Gang Zhang
Journal:  Am J Transl Res       Date:  2017-09-15       Impact factor: 4.060

7.  [High expression of DNMT3B promotes proliferation and invasion of hepatocellular carcinoma cells via Hippo signaling pathway].

Authors:  Gaohong Dong; Fuliang Qiu; Changan Liu; Hao Wu; Yan Liu
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2019-12-30

8.  Pterostilbene leads to DNMT3B-mediated DNA methylation and silencing of OCT1-targeted oncogenes in breast cancer cells.

Authors:  Megan Beetch; Cayla Boycott; Sadaf Harandi-Zadeh; Tony Yang; Benjamin J E Martin; Thomas Dixon-McDougall; Kevin Ren; Allison Gacad; John H Dupuis; Melissa Ullmer; Katarzyna Lubecka; Rickey Y Yada; Carolyn J Brown; LeAnn J Howe; Barbara Stefanska
Journal:  J Nutr Biochem       Date:  2021-07-07       Impact factor: 6.048

9.  Chromatin remodellers Brg1 and Bptf are required for normal gene expression and progression of oncogenic Braf-driven mouse melanoma.

Authors:  Patrick Laurette; Sébastien Coassolo; Guillaume Davidson; Isabelle Michel; Giovanni Gambi; Wenjin Yao; Pierre Sohier; Mei Li; Gabrielle Mengus; Lionel Larue; Irwin Davidson
Journal:  Cell Death Differ       Date:  2019-05-07       Impact factor: 12.067

Review 10.  mTOR-Rictor-EGFR axis in oncogenesis and diagnosis of glioblastoma multiforme.

Authors:  M Janaki Ramaiah; K Rohil Kumar
Journal:  Mol Biol Rep       Date:  2021-06-16       Impact factor: 2.316

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.